$45.58
-1.93 (-4.06%)
Open$47.51
Previous Close$47.51
Day High$47.74
Day Low$45.47
52W High$72.36
52W Low$20.18
Volume—
Avg Volume362.2K
Market Cap1.37B
P/E Ratio7.01
EPS$3.34
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+13.6% upside
Current
$45.58
$45.58
Target
$51.79
$51.79
$39.42
$51.79 avg
$66.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.63M | 29.26M | 183.45M |
| Net Income | 105.28M | 65.04M | 2.09M |
| Profit Margin | 247.0% | 234.6% | 1.1% |
| EBITDA | 25.98M | 16.94M | 3.06M |
| Free Cash Flow | — | — | 1.04M |
| Rev Growth | +45.7% | +45.7% | +5.3% |
| Debt/Equity | 24.23 | 24.23 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |